瑞舒伐他汀联合普罗布考对老年期脑梗死疗效及相关因素影响的研究

《瑞舒伐他汀联合普罗布考对老年期脑梗死疗效及相关因素影响的研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号13520HebeiMedicalUniversity硕士学位论文在职科学学位瑞舒伐他汀联合普罗布考对老年期脑梗死疗效及相关因素影响的研究学位申请人：马丽苹导师：王晓鹏教授专业：神经病学二级学院：第二医院2015年3月河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师(或指导小组)的指导下，由本人独立完成。本学位论文研究所获得的研究成果,其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用。凡发表与学位论文主要内容相关的论文,第一署名为单位河北医科大学，试验材料、原始数据、申报的专利等

2、知识产权均归河北医科大学所有。否则，承担相应法律责任。研究生签名：4导师签章:学院领导盖章：I严年•月曰河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加以标注和致谢等内容外,文中不包含其他人已经发表或撰写的研究成果,指导教师对此进行了审定。本论文由本人独立撰写,文责自负。研究生签名：知冬导师签章：目录中文摘要··············································································1英文摘要················

3、······························································5研究论文瑞舒伐他汀联合普罗布考对老年期脑梗死疗效及相关因素影响的研究前言··············································································10材料与方法·····································································10结果························

4、······················································12附表··············································································15讨论··············································································19结论···························································

5、···················21参考文献········································································21综述老年缺血性脑卒中危险因素与干预措施的研究进展···············24致谢····················································································35个人简历·················································

6、·····························36中文摘要瑞舒伐他汀联合普罗布考对老年期脑梗死疗效及相关因素影响的研究摘要目的：脑梗死是一种严重威胁人类健康的疾病，也是老年人最常见的脑血管病之一。随着人们生活水平的提高，脑梗死的发病率、复发率近来呈逐年上升的趋势，病死率和致残率亦常年居高不下。随着我国老龄化的进程，有数据显示，到2030年我国60岁以上的人群中将有超过3亿人罹患脑卒中，其中90%以上为缺血性卒中。这将给家庭和社会带来巨大的压力。瑞舒伐他汀是一种新型他汀类药物，主要作用在肝脏，能促进低密度脂蛋白的吸收和分解，降低血浆中胆固醇的浓度

7、，同时还具有抗炎、抗氧化、改善内皮细胞功能、调节免疫的作用。普罗布考除降脂作用外，还具有抗氧化、抗炎、保护血管内皮功能、稳定动脉粥样硬化斑块的作用。它是美国FDA唯一认证的抗氧化药物。目前对于瑞舒伐他汀联合普罗布考治疗脑梗死，尤其是对80岁以上脑梗死患者的疗效研究不多。故设计此研究旨在进一步了解瑞舒伐他汀联合普罗布考治疗老年期脑梗死及对其相关因素的影响。方法：选择2013年3月至2014年12月白求恩国际和平医院干部病房神经内科病区收治的80岁以上脑梗死患者120例。纳入病例均符合《中国脑血管病防治指南》诊断标准：⑴经颅脑CT或MRI检查确诊为脑梗死患者。

8、⑵颈动脉彩色多普勒检查确定颈动脉内膜中层厚度即CA-IMT≥1．2